CoChat
Sign Up
Cited by 101Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryMesenchymal stem cell research

The DOI matches its Crossref record; 261 of the 265 references it cites were found in a registry or an index.

Extracellular vesicles as personalized medicine

Open access
Beetler, Danielle J., Di Florio, Damian N., Bruno, Katelyn A., Ikezu, Tsuneya, March, Keith L., Cooper, Leslie T., Wolfram, Joy, Fairweather, DeLisa·2023·Molecular Aspects of Medicine
DOI 10.1016/j.mam.2022.101155PMC PMC10073244
Open this paper in CoChat — free accountOpen PDF

Abstract

Extracellular vesicles (EVs) are released from all cells in the body, forming an important intercellular communication network that contributes to health and disease. The contents of EVs are cell source-specific, inducing distinct signaling responses in recipient cells. The specificity of EVs and their accumulation in fluid spaces that are accessible for liquid biopsies make them highly attractive as potential biomarkers and therapies for disease. The duality of EVs as favorable (therapeutic) or unfavorable (pathological) messengers is context dependent and remains to be fully determined in homeostasis and various disease states. This review describes the use of EVs as biomarkers, drug delivery vehicles, and regenerative therapeutics, highlighting examples involving viral infections, cancer, and neurological diseases. There is growing interest to provide personalized therapy based on individual patient and disease characteristics. Increasing evidence suggests that EV biomarkers and therapeutic approaches are ideal for personalized medicine due to the diversity and multifunctionality of EVs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mam.2022.101155

Cites

261 of 261 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Biogenic Nanoparticles. Biogenic nanoparticles include extracellular vesicles (EVs) and other nanosized extracellular particles. Newer inclusions are exomeres: non-membranous nanoparticles smaller than 50 nm, with functional contents secreted by cells (H. Zhang et al., 2018), oncosomes: EVs released from cancer cells ranging between 100 nm and 4 μm (Meehan et al., 2016), and migrasomes: large nano- and microvesicles used for cell migration and intercellular signaling (da Rocha-Azevedo and Schmid, 2015; Ma et al., 2015). More well-established nanoparticles include lipoproteins (Feingold, 2000), viruses (Louten, 2016), and protein aggregates (Goodsell and Olson, 1993). This figure was created in ©BioRender-biorender.com.
Fig. 1. Biogenic Nanoparticles. Biogenic nanoparticles include extracellular vesicles (EVs) and other nanosized extracellular particles. Newer inclusions are exomeres: non-membranous nanoparticles smaller than 50 nm, with functional contents secreted by cells (H. Zhang et al., 2018), oncosomes: EVs released from cancer cells ranging between 100 nm and 4 μm (Meehan et al., 2016), and migrasomes: large nano- and microvesicles used for cell migration and intercellular signaling (da Rocha-Azevedo and Schmid, 2015; Ma et al., 2015). More well-established nanoparticles include lipoproteins (Feingold, 2000), viruses (Louten, 2016), and protein aggregates (Goodsell and Olson, 1993). This figure was created in ©BioRender-biorender.com.CC BY-NC-ND · PubMed Central
Fig. 2. EVs in Pathology. Many studies have linked EVs to the pathogenesis of various diseases, references are listed in Supplement Table 1. The figure depicts a variety of these diseases, grouped by major organ system. This list is constantly growing. This figure was created in ©BioRender-biorender.com.
Fig. 2. EVs in Pathology. Many studies have linked EVs to the pathogenesis of various diseases, references are listed in Supplement Table 1. The figure depicts a variety of these diseases, grouped by major organ system. This list is constantly growing. This figure was created in ©BioRender-biorender.com.CC BY-NC-ND · PubMed Central
Fig. 3. EVs Impact the Hallmarks of Cancer. Hallmarks of cancer promoted by EVs depicted in green, other cancer promoters in grey. Adapted from “Hallmarks of cancer (2011 update), including emerging hallmarks and enabling factors”, by ©BioRender-biorender.com. Retrieved from https://app.biorender.com/biorender-templates.
Fig. 3. EVs Impact the Hallmarks of Cancer. Hallmarks of cancer promoted by EVs depicted in green, other cancer promoters in grey. Adapted from “Hallmarks of cancer (2011 update), including emerging hallmarks and enabling factors”, by ©BioRender-biorender.com. Retrieved from https://app.biorender.com/biorender-templates.CC BY-NC-ND · PubMed Central
Fig. 4. Representative image of dSTORM tetraspanin profiling of an EV. CD9 (yellow), CD81 (teal), CD63 (purple) using ONI EV profiling kit and precision depiction. Scale bar: 100 nm.
Fig. 4. Representative image of dSTORM tetraspanin profiling of an EV. CD9 (yellow), CD81 (teal), CD63 (purple) using ONI EV profiling kit and precision depiction. Scale bar: 100 nm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

Sorted by citations

See all 101

Related

See all

Metadata

Authors
Beetler, D. J., Di Florio, D. N., Bruno, K. A., Ikezu, T., March, K. L., Cooper, L. T., Wolfram, J., & Fairweather, D.
Affiliations
  • Mayo Clinic (US)
  • University of Florida (US)
  • Mayo Clinic in Florida (US)
  • The University of Queensland (AU)
Corresponding author
Fairweather, DeLisa
ORCID
Venue
Molecular Aspects of Medicine
Publisher
Elsevier BV
Published
2023-06
Volume
91
Pages
101155
ISSN
0098-2997 (ISSN-L)
DOI
10.1016/j.mam.2022.101155
PMC
PMC10073244
OpenAlex
W4310099811
Cited by
101
References
265
Citations by year
2026: 23 · 2025: 30 · 2024: 28 · 2023: 20
FWCI
2.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Aspects of Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • American Heart Association (R01 HL164520, 20TPA35490415, TL1 TR002380, R21 AI154927, R21 AI145356, R21 AI163302, R21 AI152318)
  • Ionis Pharmaceuticals
  • National Institutes of Health (20TPA35490415, UL1TR002556, AI154927, TR002380, TL1TR002380, UL1TR002377)
  • Advanced Research Projects Agency
  • National Institute on Aging (R01AG066429, RF1AG054199, R01AG054672, R01AG067763, R01AG072719, R01AG054199, R01AG076537)
  • National Heart, Lung, and Blood Institute (HL164520, R01HL164520)
  • National Institute of Allergy and Infectious Diseases (R21AI145356, 20TPA35490415, AI145356, R21AI163302, R21AI152318, R21AI154927)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
extracellular vesicles, personalized medicine, liquid biopsy, biomarkers, drug carriers, intercellular communication, viral infection, cancer, neurological disorders
MeSH terms
Extracellular Vesicles, Liquid Biopsy, Humans, Biomarkers, Drug Delivery Systems, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review